Jose Ricardo Perez has a rich background in oncology and has been instrumental in the development of innovative cancer treatments at Exelixis. His extensive experience in the pharmaceutical industry, including roles at Novartis, has equipped him with a strategic perspective and vision that has led to significant discoveries and successful outcomes. Perez's leadership at Exelixis has been marked by a commitment to patient care and a focus on delivering results and new medicines to treat and defeat cancer. His work has not only advanced the company but also contributed to the broader field of oncology by providing hope and new treatments for cancer patients.
Speaker Interview
Would you be able to share a few sentences about why your session is so important for today’s EAP landscape, as well as what you will be discussing?
- Changes into the EAP situation in 2026 after the 2025 guidance from the FDA
- Defining the ideal moment to launch an EAP in the life cycle of a drug
- What data can we get from an EAP?
- Challenges to implement a Global EAP
- Which team should manage an EAP?
How has Expanded Access changed in the last 12–18 months - and what’s driving that shift?
- The recently issued FDA guidelines have changed the EAP in the last months. There are substantial changes in the regulatory framework
What are the biggest challenges being faced by expanded access teams today?
- Expanded Access teams today are under pressure to deliver faster, more transparent, and more consistent access decisions - while managing limited supply, regulatory complexity, internal misalignment, and growing external scrutiny.
What’s something the industry isn’t talking about enough?
- The cumulative human and organizational cost of Expanded Access decision-making. The real blind spot is the sustained emotional, ethical, and cultural load placed on Expanded Access teams—and how poorly organizations are designed to absorb it.
What will your session cover and what will it help teams overcome?
- How Expanded Access expectations have matured without fundamentally changing the legal framework
- Why teams can no longer rely on ad hoc processes once programs scale
- What it means to “operationalize” Expanded Access in practice
What are you most looking forward to at the summit?
- I’m most looking forward to the candid, peer‑to‑peer conversations - sharing real lessons learned with teams who are navigating the same operational, ethical, and cross‑functional challenges of delivering Expanded Access in today’s environment.
Jose Ricardo Perez
Vice President, Genitourinary Portfolio, Medical Affairs Exelixis, Inc.
Explore the Agenda
Uncover practical insights from leading access, operations, and medical affairs experts through real-world case studies, interactive discussions, and hands-on workshops designed to help you build, manage, and scale compliant, patient-focused Expanded Access Programs worldwide.
Partner With Us
Showcase how your solutions empower sponsors to operationalize access - from supply chain and digital workflow tools to regulatory consultancy and real-world data systems.
Join the Global EAP Community
Be part of the only west coast EAP focused meeting uniting 70+ access leaders across pharma, biotech, and service providers. Exchange practical experience, shape global best practices, and collaborate on solutions that advance equitable, ethical, and scalable access for patients in need.